المؤلفون: Orton Alison

المصدر: Jahrbuch für Wirtschaftsgeschichte, Vol 65, Iss 1, Pp 155-178 (2024)

مصطلحات موضوعية: labor history, migration, identity, nationalism, arbeitergeschichte, identität, nationalismus, j 51, j 61, Economic history and conditions, HC10-1085, Economics as a science, HB71-74

وصف الملف: electronic resource

Relation: https://doaj.org/toc/0075-2800; https://doaj.org/toc/2196-6842

URL الوصول: https://doaj.org/article/2b39cda57647416d8a2c763951893ca2

المؤلفون: Bapiro TE; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.) tashinga.bapiro1@astrazeneca.com dermot.f.mcginnity@astrazeneca.com., Martin S; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Wilkinson SD; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Orton AL; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Hariparsad N; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Harlfinger S; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., McGinnity DF; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.).

المصدر: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Jul; Vol. 51 (7), pp. 892-901. Date of Electronic Publication: 2023 Apr 11.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics, etc.] Country of Publication: United States NLM ID: 9421550 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-009X (Electronic) Linking ISSN: 00909556 NLM ISO Abbreviation: Drug Metab Dispos Subsets: MEDLINE

مواضيع طبية MeSH: Microsomes, Liver*/metabolism , Aryl Hydrocarbon Hydroxylases*/metabolism, Humans ; NADP/metabolism ; Hepatocytes/metabolism ; Cytochrome P-450 Enzyme System/metabolism ; Metabolic Clearance Rate

المؤلفون: Jones BL; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Orton AL; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Tindall SW; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Christensen JT; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Enosakhare O; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Russell KA; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Robins AM; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Larriviere-McCarl A; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Sandres J; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Cox B; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Thomas C; Department of Psychology, Brigham Young University, Provo, UT 84602, USA., Reynolds C; Department of Psychology, Brigham Young University, Provo, UT 84602, USA.

المصدر: Children (Basel, Switzerland) [Children (Basel)] 2023 May 27; Vol. 10 (6). Date of Electronic Publication: 2023 May 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101648936 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9067 (Print) Linking ISSN: 22279067 NLM ISO Abbreviation: Children (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Douthwaite JA; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. julie.douthwaite@astrazeneca.com., Brown CA; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK. christopher.brown@crl.com., Ferdinand JR; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Sharma R; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Elliott J; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Taylor MA; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Malintan NT; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Duvoisin H; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hill T; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK., Delpuech O; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Orton AL; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Pitt H; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Kuenzi F; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK., Fish S; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.; GSK R&D Tech, Stevenage, UK., Nicholls DJ; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Cuthbert A; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Richards I; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK., Ratcliffe G; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK., Upadhyay A; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Marklew A; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK., Hewitt C; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ross-Thriepland D; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Brankin C; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Chodorge M; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Browne G; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Mander PK; GSK R&D, Stevenage, UK., DeWildt RM; GSK R&D, Stevenage, UK., Weaver S; GSK R&D Tech, Stevenage, UK., Smee PA; GSK R&D Tech, Stevenage, UK., van Kempen J; GSK R&D, Stevenage, UK., Bartlett JG; GSK R&D, Stevenage, UK., Allen PM; GSK R&D, Stevenage, UK., Koppe EL; GSK R&D, Stevenage, UK., Ashby CA; GSK R&D, Stevenage, UK., Phipps JD; GSK R&D, Stevenage, UK., Mehta N; GSK R&D, Stevenage, UK., Brierley DJ; GSK R&D, Stevenage, UK., Tew DG; GSK R&D, Stevenage, UK., Leveridge MV; GSK R&D, Stevenage, UK., Baddeley SM; GSK R&D, Stevenage, UK., Goodfellow IG; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK., Green C; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Abell C; Vice Chancellor's Office, University of Cambridge, Cambridge, UK., Neely A; Vice Chancellor's Office, University of Cambridge, Cambridge, UK., Waddell I; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK., Rees S; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Maxwell PH; School of Clinical Medicine, University of Cambridge, Cambridge, UK., Pangalos MN; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Howes R; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Clark R; Charles River Laboratories, Chesterford Research Park, Saffron Walden, UK.

المصدر: Scientific reports [Sci Rep] 2022 Feb 24; Vol. 12 (1), pp. 3114. Date of Electronic Publication: 2022 Feb 24.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep

مواضيع طبية MeSH: COVID-19*/diagnosis , COVID-19*/virology , SARS-CoV-2*/isolation & purification , SARS-CoV-2*/genetics , COVID-19 Testing*/methods, Humans ; United Kingdom ; Laboratories

المؤلفون: Delpuech O; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Douthwaite JA; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. Julie.douthwaite@astrazeneca.com.; In Vivo Expressed Biologics, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK. Julie.douthwaite@astrazeneca.com., Hill T; Charles River Laboratories, Chesterford Research Park, Saffron Walden, CB10 1XL, UK., Niranjan D; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Malintan NT; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Duvoisin H; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Elliott J; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Goodfellow I; Division of Virology, Department of Pathology, Addenbrooke's Hospital, Cambridge, UK., Hosmillo M; Division of Virology, Department of Pathology, Addenbrooke's Hospital, Cambridge, UK., Orton AL; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Taylor MA; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Brankin C; Biologics Engineering, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Pitt H; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Animal Science and Technologies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Ross-Thriepland D; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Siek M; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Facilities Management, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Cuthbert A; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.; Clinical Operations, Late-Stage Development, Oncology R&D, AstraZeneca, Cambridge, UK., Richards I; Charles River Laboratories, Chesterford Research Park, Saffron Walden, CB10 1XL, UK., Ferdinand JR; Charles River Laboratories, Chesterford Research Park, Saffron Walden, CB10 1XL, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Barker C; BiologIC Technologies Ltd., Soham, UK., Shaw R; Oral Product Development, Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, UK., Ariani C; Wellcome Sanger Institute, Hinxton, UK., Waddell I; Charles River Laboratories, Chesterford Research Park, Saffron Walden, CB10 1XL, UK., Rees S; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Green C; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Clark R; Charles River Laboratories, Chesterford Research Park, Saffron Walden, CB10 1XL, UK., Upadhyay A; BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Howes R; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.

المصدر: Scientific reports [Sci Rep] 2022 Feb 21; Vol. 12 (1), pp. 2883. Date of Electronic Publication: 2022 Feb 21.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Validation Study

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

مواضيع طبية MeSH: Hot Temperature* , Virus Inactivation*, COVID-19/*diagnosis , COVID-19 Nucleic Acid Testing/*methods , Containment of Biohazards/*methods , Real-Time Polymerase Chain Reaction/*methods , SARS-CoV-2/*genetics , Specimen Handling/*methods, Animals ; COVID-19/virology ; Cell Line ; Humans ; Mice ; Murine hepatitis virus/genetics ; RNA, Viral/genetics ; RNA, Viral/isolation & purification ; Sensitivity and Specificity

المؤلفون: Degorce SL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States. Electronic address: sebastien.degorce@astrazeneca.com., Aagaard A; Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden., Anjum R; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Cumming IA; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Diène CR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Fallan C; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Johnson T; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Leuchowius KJ; Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden., Orton AL; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Pearson S; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Robb GR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Rosen A; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Boston, 35 Gatehouse Drive, Waltham, MA 02451, United States., Scarfe GB; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Scott JS; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Smith JM; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Steward OR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Terstiege I; Medicinal Chemistry, R&I, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden., Tucker MJ; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Turner P; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Wilkinson SD; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Wrigley GL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Xue Y; Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden.

المصدر: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2020 Dec 01; Vol. 28 (23), pp. 115815. Date of Electronic Publication: 2020 Oct 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 9413298 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3391 (Electronic) Linking ISSN: 09680896 NLM ISO Abbreviation: Bioorg Med Chem Subsets: MEDLINE

مواضيع طبية MeSH: Interleukin-1 Receptor-Associated Kinases/*antagonists & inhibitors , Protein Kinase Inhibitors/*metabolism , Quinazolines/*chemistry, Aldehyde Oxidase/metabolism ; Animals ; Binding Sites ; Cell Line, Tumor ; Cell Survival/drug effects ; Crystallography, X-Ray ; Dogs ; Drug Stability ; Half-Life ; Hepatocytes/metabolism ; Humans ; Interleukin-1 Receptor-Associated Kinases/metabolism ; Mice ; Microsomes, Liver/metabolism ; Molecular Dynamics Simulation ; Protein Kinase Inhibitors/chemistry ; Protein Kinase Inhibitors/pharmacology ; Quinazolines/metabolism ; Quinazolines/pharmacology ; Rats ; Structure-Activity Relationship

المؤلفون: Wilkinson SD; DMPK/ADME Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Martin S; DMPK/ADME Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Orton AL; DMPK/ADME Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Markandu R; DMPK/ADME Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Jones BC; DMPK/ADME Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.

المصدر: Rapid communications in mass spectrometry : RCM [Rapid Commun Mass Spectrom] 2020 May 30; Vol. 34 (10), pp. e8735.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley And Sons Ltd Country of Publication: England NLM ID: 8802365 Publication Model: Print Cited Medium: Internet ISSN: 1097-0231 (Electronic) Linking ISSN: 09514198 NLM ISO Abbreviation: Rapid Commun Mass Spectrom Subsets: PubMed not MEDLINE; MEDLINE

المؤلفون: Lonsdale R; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK., Burgess J; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK., Colclough N; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK., Davies NL; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK., Lenz EM; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK., Orton AL; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK., Ward RA; Chemistry and DMPK, Oncology, IMED Biotech Unit, AstraZeneca , Cambridge CB4 0WG, UK.

المصدر: Journal of chemical information and modeling [J Chem Inf Model] 2017 Dec 26; Vol. 57 (12), pp. 3124-3137. Date of Electronic Publication: 2017 Nov 21.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101230060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-960X (Electronic) Linking ISSN: 15499596 NLM ISO Abbreviation: J Chem Inf Model Subsets: MEDLINE

مواضيع طبية MeSH: Acrylamides/*pharmacology , Cysteine/*metabolism , Drug Discovery/*methods , Glutathione/*metabolism, Acrylamides/chemistry ; Cysteine/chemistry ; Glutathione/chemistry ; Humans ; Models, Molecular ; Molecular Targeted Therapy ; Structure-Activity Relationship

المؤلفون: Martin S; Oncology iMED, Hodgkin Building, Chesterford Science Park, AstraZeneca UK Ltd., Saffron Walden, Essex, CB10 1XL, UK., Lenz EM; Oncology iMED, Hodgkin Building, Chesterford Science Park, AstraZeneca UK Ltd., Saffron Walden, Essex, CB10 1XL, UK., Smith R; Oncology iMED, Alderley Park, AstraZeneca UK Ltd., Macclesfield, Cheshire, SK10 4TG, UK., Temesi DG; Oncology iMED, Alderley Park, AstraZeneca UK Ltd., Macclesfield, Cheshire, SK10 4TG, UK.; (DGT) Recipharm, Vale of Bardsley, Ashton-under-Lyne, Lancashire, OL7 9RR, UK., Orton AL; Oncology iMED, Hodgkin Building, Chesterford Science Park, AstraZeneca UK Ltd., Saffron Walden, Essex, CB10 1XL, UK., Clench MR; Biomedical Research Centre, Sheffield Hallam University, Howard Street, Sheffield, S1 1WB, UK.

المصدر: Rapid communications in mass spectrometry : RCM [Rapid Commun Mass Spectrom] 2017 Jan 15; Vol. 31 (1), pp. 145-151.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley And Sons Ltd Country of Publication: England NLM ID: 8802365 Publication Model: Print Cited Medium: Internet ISSN: 1097-0231 (Electronic) Linking ISSN: 09514198 NLM ISO Abbreviation: Rapid Commun Mass Spectrom Subsets: MEDLINE

مواضيع طبية MeSH: Aldehydes/*metabolism , Chromatography, High Pressure Liquid/*methods , Mass Spectrometry/*methods , Methanol/*metabolism , Microsomes, Liver/*metabolism , Piperidines/*metabolism, Aldehydes/analysis ; Aldehydes/chemistry ; Glutathione ; Humans ; Hydroxylamines ; Methanol/analysis ; Methanol/chemistry ; Piperidines/chemistry